Angie Mae Rodday, PhD¹, Susan K. Parsons, MD, MRCP¹, Jonathan W. Friedberg, MD, MMSc², Andrea Gallamini, MD³, Eliza Hawkes, MD⁴, David C. Hodgson, MD, MPH, FRCPC^5*, Peter Johnson, MD, FRCP⁶, Brian K. Link, MD⁷, Eric Mou, MD⁷, Kerry J. Savage, MD, MSc, FRCPC⁸, Jenica Upshaw, MD^9*, Pier Luigi Zinzani, MD, PhD¹⁰, Matthew J. Maurer, DSc¹¹ and Andrew M. Evens, DO, MBA, MMSc¹²

¹Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA
²James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY
³Research and Clinical Innovation Department, Antoine Lacassagne Cancer Center, Nice, France
⁴Department of Medical Oncology and Haematology, Olivia Newton-John Cancer Research Institute, Melbourne, Australia
⁵Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
⁶Southampton General Hospital School of Medicine, Southampton, United Kingdom
⁷Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
⁸BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC, Canada
⁹The CardioVascular Center and Advanced Heart Failure Program, Tufts Medical Center, Boston, MA
¹⁰IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli”Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
¹¹Department of Quantitative Health Sciences Research, Mayo Clinic, Rochester, MN
¹²Division of Blood Disorders, Rutgers Cancer Institute New Jersey, New Brunswick, NJ

Hun Lee, MD^1*, Ian W. Flinn, MD PhD², Jason Melear, MD³, Rod Ramchandren, MD⁴, Judah Friedman, MD^5*, John M. Burke, MD³, Yuliya Linhares, MD^3*, Paul Alan Gonzales, MD^6*, Mihir Raval^3*, Rangaswamy Chintapatla, MD⁷, Tatyana Feldman, MD⁸, Habte A. Yimer³, Miguel Islas-Ohlmayer^3,9*, Asad Dean^3*, Vishal Rana, MD^10*, Mitul Gandhi, MD³, John Renshaw, MD^3*, Linda Ho, MD¹¹, Michelle A. Fanale, MD¹¹, Wenchuan Guo^11* and Christopher A. Yasenchak, MD¹²

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
³US Oncology Research, The Woodlands, TX
⁴University of Tennessee, Knoxville, TN
⁵University Hospitals Seidman Cancer Center, Cleveland, OH
⁶Brooke Army Medical Center, Fort Sam Houston, TX
⁷Kadlec Clinic, Kennewick, WA
⁸Lymphoma Division, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ
⁹Oncology Hematology Care, Cincinnati, OH
¹⁰University of Colorado Health Hematology and Oncology, Colorado Springs, CO
¹¹Seagen Inc., Bothell, WA
¹²Willamette Valley Cancer Institute and Research Center, Eugene, OR

Stefano Luminari, MD¹, Alexander Fosså, MD, PhD^2*, Judith Trotman, FRACP³, Daniel Molin^4*, Francesco Annibale d'Amore, MD, DMSc⁵, Gunilla Enblad, MD, PhD^6*, Leanne Berkahn, MD^7*, Sally F Barrington, Prof, MD, PhD^8*, John Radford, MD, FRCPath, FMedSci^9*, Massimo Federico, MD¹⁰, Amy A. Kirkwood, MSc^11* and Peter Johnson, MD, FRCP¹²

¹Hematology IRCCS Reggio Emilia, Reggio Emilia, Italy
²Department of Oncology, Oslo University Hospital, Oslo, Norway
³Department of Haematology, Concord Hospital, Concord, NSW, Australia
⁴Department of Immunology, Genetics, and Pathology, Clinical and Experimental Oncology, Uppsala University, Uppsala Akademiska Hospital, Uppsala, Sweden
⁵Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
⁶Dept of Oncology, Akademiska University Hospital, Uppsala, Sweden
⁷Department of Haematology, Auckland City Hospital, Auckland, New Zealand
⁸School of Biomedical Engineering and Imaging Sciences, King’s College London and Guys’ & St Thomas PET Imaging Centre, London, Kent, United Kingdom
⁹University of Manchester, Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
¹⁰CHIMOMO department, Università degli Studi di Modena e Reggio Emilia, Modena, Italy
¹¹Cancer Research UK & UCL Cancer Trials Centre, University College London, London, United Kingdom
¹²School of Cancer Sciences, University of Southampton, Southampton, United Kingdom

John Timmerman, MD¹, David Lavie, MD^2*, Nathalie A. Johnson, MD, PhD,³, Abraham Avigdor, MD⁴, Peter Borchmann⁵, Charalambos Andreadis, MD, MSCE^6*, Ali Bazargan, MBBS FRACP FRCPA^7*, Gareth P. Gregory, MBBS, PhD, FRACP, FRCPA⁸, Colm Keane, MB, BCh, BAO, MRCPI, MSc, MBA, FRCPath, PhD^9*, Inna Tzoran, MD^10*, Vladan Vucinic, MD^11*, Pier Luigi Zinzani, MD, PhD¹², Rachel Marceau West^13*, Pallavi Pillai^13*, Akash Nahar, MD, MPH^13* and Alex F. Herrera, MD¹⁴

¹UCLA Medical Center, Los Angeles, CA
²Hadassah Medical Center, Jerusalem, Israel
³Jewish General Hospital, Montreal, QC, Canada
⁴Chaim Sheba Medical Center, Ramat Gan, Israel
⁵U. klinikum Koeln AOER, Cologne, Germany
⁶UCSF, San Francisco, CA
⁷University of Melbourne, Melbourne, VIC, Australia; St Vincent’s Hospital, Fitzroy, VIC, Australia
⁸School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia
⁹Princess Alexandra Hospital, Brisbane, QLD, Australia
¹⁰Rambam Health Care Campus, Haifa, Israel
¹¹Leipzig University Medical Center, Clinic and Policlinic for Hematology, Cell Therapy and Hemostaseology, Leipzig, Germany
¹²IRCCS-University Hospital of Bologna Seragnoli Institute of Hematology and Department of Specialized, Diagnostic, and Experimental Medicine, University of Bologna, Bologna, Italy
¹³Merck & Co., Inc., Rahway, NJ
¹⁴City of Hope, Duarte, CA

Peter Borchmann¹, Alden Moccia, M.D.^2*, Richard Greil, MD^3,4, Mark Hertzberg, MD⁵, Valdete Schaub, MD^6*, Andreas Hüttmann, MD⁷, Felix Keil^8*, Judith Dierlamm, MD^9*, Mathias Haenel, MD^10*, Urban Novak^11*, Julia Meissner, MD^12*, Andreas Zimmermann, MD^13*, Stephan Mathas, MD^14*, Josée M. Zijlstra, MD PhD¹⁵, Alexander Fosså, MD, PhD^16*, Andreas Viardot, MD¹⁷, Bernd Hertenstein, MD^18*, Sonja Martin, MD^19*, Pratyush Giri, MBBS^20*, Peter Kamper^21*, Daniel Molin^22*, Stefanie Kreissl^23*, Michael Fuchs, MD^24,25*, Gundolf Schneider^26*, Andreas Rosenwald^27*, Wolfram Klapper, MD^28*, Hans Eich, MD^29*, Christian Baues, MD^30*, Michael Hallek, MD³¹, Markus Dietlein, MD^32*, Carsten Kobe, MD^33*, Volker Diehl, MD³⁴ and Andreas Engert, MD^35,36

¹German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany
²Division of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
³Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT), Salzburg, Austria and Cancer Cluster Salzburg (CCS), Salzburg, Austria
⁴AGMT, Salzburg, Austria
⁵Department of Clinical Haematology, Westmead Hospital, Randwick, NSW, Australia
⁶Medizinische Klinik II, Universitätsklinikum Tübingen, Tübingen, Germany
⁷Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, NRW, Germany
⁸3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Vienna, Austria
⁹Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
¹⁰Department of Hematology, Oncology and Bone Marrow Transplantation, Klinikum Chemnitz, Chemnitz, Germany
¹¹Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
¹²Medicine V, University of Heidelberg, Heidelberg, Germany
¹³Department of Hematology/Oncology, University Hospital of Munich, LMU Munich, Munich, Germany
¹⁴Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
¹⁵Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands, Amsterdam, Netherlands
¹⁶Department of Oncology, Oslo University Hospital, Oslo, Norway
¹⁷Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
¹⁸Klinikum Bremen Mitte, Bremen, Germany
¹⁹Department of Hematology and Oncology, Robert-Bosch-Hospital, Stuttgart, Germany
²⁰Royal Adelaide Hospital, Adelaide, SA, Australia
²¹Department of Hematology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark
²²Department of Immunology, Genetics, and Pathology, Clinical and Experimental Oncology, Uppsala University, Uppsala Akademiska Hospital, Uppsala, Sweden
²³German Hodgkin Study Group, University Hospital Cologne, Köln, DEU
²⁴German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany
²⁵University of Cologne, German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany
²⁶German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany
²⁷Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany
²⁸Department of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
²⁹Department of Radiotherapy, University Hospital of Muenster, Muenster, Germany
³⁰Department of Radiooncology and Cyberknife Center, Faculty of Medicine and University of Cologne, Cologne, Germany
³¹Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany
³²Faculty of Medicine and University Hospital Cologne, University Hospital of Cologne, Department of Nuclear Medicine, Cologne, Germany
³³Department of Nuclear Medicine. Faculty of Medicine and University of Cologne, Cologne, Germany
³⁴German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany
³⁵Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
³⁶University of Cologne, German Hodgkin Study Group (GHSG), Cologne, Germany

Matthew Mei, MD¹, Joycelynne Palmer, PhD^2*, Ni-Chun Tsai, MS^3*, Hun Ju Lee, MD⁴, Iris Isufi, MD⁵, Leslie L. Popplewell, MD, FACP, MPH⁶, Lynne Smith^7*, Lacolle Peters^8*, Lara Rodriguez^8*, James Godfrey, MD⁹, John H. Baird, MD⁸, Joo Y. Song, MD¹⁰, Steven T. Rosen, MD¹¹, Larry W. Kwak, MD, PhD¹², Stephen J Forman, MD¹³ and Alex F. Herrera, MD¹⁴

¹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
²Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, CA
³Department of Computational and Quantitative Medicine-BRI, City of Hope National Medical Center, Duarte, CA
⁴Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Hematology, Yale University School of Medicine, New Haven, CT
⁶Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
⁷Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Stem Cell Transplantation, Beckman Research Institute of the City of Hope, City of Hope National Medical Center, Duarte, CA
⁸City of Hope National Medical Center, Duarte, CA
⁹City of Hope Comprehensive Cancer Center, Duarte, CA
¹⁰Department of Pathology, City of Hope National Medical Center, Duarte, CA
¹¹Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA
¹²Deputy Director, City of Hope Comprehensive Cancer Center, Duarte, CA
¹³Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
¹⁴City of Hope, Duarte, CA